Retrophin Inc. Cmn (RTRX) 18.57 $RTRX Bristol-Myers,

New Post Public Reply Private Reply Replies (0) Message Board

Jul 11, 2016 at 2:05 PM

Retrophin Inc. Cmn (RTRX) 18.57 $RTRX

Bristol-Myers, PsiOxus Strike Immuno-Oncology Collaboration
Zacks Equity Research - Zacks Investment Research - Fri Jul 01, 7:28AM CDT
Bristol-Myers (BMY) inked a clinical collaboration agreement with PsiOxus Therapeutics for the evaluation of a combination of Opdivo and enadenotucirev.
ANIP: 55.70 (-0.81), PFE: 36.32 (+0.20), RTRX: 18.57 (-0.08), BMY: 75.66 (+0.38)

Horizon (HZNP) Stock Up on Ravicti Label Expansion Filing
Zacks Equity Research - Zacks Investment Research - Thu Jun 30, 9:11AM CDT
Horizon Pharma (HZNP) announced that it is looking to expand the approved age range for Ravicti for chronic management of urea cycle disorders in the U.S.
ANIP: 55.70 (-0.81), HZNP: 19.08 (+0.37), RTRX: 18.57 (-0.08), BMY: 75.66 (+0.38)

Endo's Stock Gains on Vasostrict's New Patent Approval
Zacks Equity Research - Zacks Investment Research - Wed Jun 29, 9:38AM CDT
Endo International???s (ENDP) shares jumped 18.3% after the company announced that the U.S. Patent and Trademark Office has issued a new patent for Vasostrict.
ENDP: 17.32 (-0.10), ANIP: 55.70 (-0.81), RTRX: 18.57 (-0.08), BMY: 75.66 (+0.38)

Integra Life Sciences Forges Ahead with Expansion Plans
Zacks Equity Research - Zacks Investment Research - Tue Jun 28, 5:06PM CDT
Integra Life Sciences (IART) recently received FDA approval for its Integra Omnigraft Dermal Regeneration Matrix.
IART: 80.54 (-0.91), HSKA: 43.38 (-0.14), FCSC: 1.19 (-0.01), RTRX: 18.57 (-0.08)

Sanofi Inks Deal to Swap Business with Boehringer Ingelheim
Zacks Equity Research - Zacks Investment Research - Mon Jun 27, 7:15AM CDT
Sanofi (SNY) signed contracts with Boehringer Ingelheim for the strategic transaction initiated in Dec 2015 regarding an exchange of their businesses.
ANIP: 55.70 (-0.81), PFE: 36.32 (+0.20), RTRX: 18.57 (-0.08), SNY: 41.50 (+0.65)

Gilead's (GILD) HIV Treatment Odefsey Gains Approval in EU
Zacks Equity Research - Zacks Investment Research - Fri Jun 24, 9:08AM CDT
Gilead Sciences' (GILD) once-daily single tablet regimen Odefsey gained EU approval for the treatment of HIV-1 infection in certain patients.
JNJ: 123.33 (+0.48), GILD: 87.04 (+0.49), ANIP: 55.70 (-0.81), RTRX: 18.57 (-0.08)

Retrophin (RTRX) RE-024 Positive in Physician-Initiated Study
Zacks Equity Research - Zacks Investment Research - Fri Jun 24, 5:54AM CDT
Retrophin (RTRX) announced new data from a physician-initiated study on RE-024 for the treatment of pantothenate kinase-associated neurodegeneration (PKAN).
ANIP: 55.70 (-0.81), PFE: 36.32 (+0.20), RTRX: 18.57 (-0.08), ORPN: 1.66 (-0.01)

Anavex's Lead Candidate Gets Orphan Drug Status Yet Again
Zacks Equity Research - Zacks Investment Research - Thu Jun 23, 5:22PM CDT
Anavex Life Sciences (AVXL) announced that ANAVEX 2-73 has been granted orphan drug status by the FDA for the treatment of infantile spasms.
AVXL: 7.79 (+0.21), ANIP: 55.70 (-0.81), RTRX: 18.57 (-0.08), ACOR: 25.97 (-0.24)

Nymox (NYMX) Stock Up on Positive 7-Year Fexapotide Data
Zacks Equity Research - Zacks Investment Research - Thu Jun 23, 7:51AM CDT
Nymox (NYMX) announced positive results from the seven-year, prospective, placebo-controlled, double-blind study on fexapotide (NX-1207).
ANIP: 55.70 (-0.81), PFE: 36.32 (+0.20), RTRX: 18.57 (-0.08), NYMX: 3.35 (-0.01)

Retrophin Announces New Data from Physician-Initiated Treatment with RE-024 at the 20th International Congress of Parkinson's Disease and Movement Disorders
GlobeNewswire - Thu Jun 23, 5:00AM CDT
Retrophin, Inc. (NASDAQ:RTRX) today announced new data from physician-initiated treatment with RE-024, the company's novel investigational replacement therapy for pantothenate kinase-associated neurodegeneration (PKAN), a rare and life-threatening genetic condition characterized by a host of progressively debilitating movement disorders. Key findings suggest RE-024 was safe and well tolerated in two adults with PKAN who experienced clinically meaningful improvements, followed by stabilization of disease progression over 47 weeks of treatment.
RTRX: 18.57 (-0.08)

Prima Reports Favorable Initial Breast Cancer Study Data
Zacks Equity Research - Zacks Investment Research - Wed Jun 22, 2:30PM CDT
Prima BioMed Ltd (PBMD) announced initial data from a phase IIb chemo-immunotherapy study on IMP321 for the treatment of metastatic breast cancer.
PBMD: 0.92 (unch), ANIP: 55.70 (-0.81), RTRX: 18.57 (-0.08), CELG: 104.46 (-0.57)

GW Pharma (GWPH) to Develop Epidiolex for Infantile Spasms
Zacks Equity Research - Zacks Investment Research - Wed Jun 22, 9:53AM CDT
GW Pharmaceuticals (GWPH) has selected infantile spasms as the fourth target indication for the development of Epidiolex.
GWPH: 97.43 (+2.60), ANIP: 55.70 (-0.81), RTRX: 18.57 (-0.08), BMY: 75.66 (+0.38)

Inovio Stock Up, Zika Vaccine Gets Nod for Phase I Study
Zacks Equity Research - Zacks Investment Research - Tue Jun 21, 3:51PM CDT
Inovio Pharmaceuticals (INO) and GeneOne Life Science will begin the first Zika vaccine study in human volunteers; Inovio's stock gains.
INO: 9.28 (+0.17), ANIP: 55.70 (-0.81), XON: 27.04 (+0.32), RTRX: 18.57 (-0.08)

Fate's (FATE) ProTmune Gets Fast Track Status, Stock Up
Zacks Equity Research - Zacks Investment Research - Tue Jun 21, 10:46AM CDT
Fate Therapeutics (FATE) announced that the FDA has granted the Fast Track status to its immunotherapy ProTmune.
FATE: 1.78 (+0.01), ANIP: 55.70 (-0.81), RTRX: 18.57 (-0.08), ACOR: 25.97 (-0.24)

Gilead Presents Favorable Preliminary Bictegravir HIV Data
Zacks Equity Research - Zacks Investment Research - Tue Jun 21, 10:21AM CDT
Gilead Sciences (GILD) presented encouraging preliminary data from four pre-clinical and phase I studies evaluating bictegravir for the treatment of HIV.
GILD: 87.04 (+0.49), ANIP: 55.70 (-0.81), RTRX: 18.57 (-0.08), BMY: 75.66 (+0.38)

Auris (EARS) Begins Phase III Study for Sudden Deafness
Zacks Equity Research - Zacks Investment Research - Mon Jun 20, 9:31AM CDT
Auris Medical (EARS) has started patient enrollment in a second pivotal phase III study (ASSENT) on AM-111 for the treatment of sudden deafness.
EARS: 4.05 (-0.04), ANIP: 55.70 (-0.81), RTRX: 18.57 (-0.08), BMY: 75.66 (+0.38)

Kura (KURA) Begins Dosing in Phase II Study on Cancer Drug
Zacks Equity Research - Zacks Investment Research - Fri Jun 17, 3:18PM CDT
Kura Oncology (KURA) announced the dosing of the first patient in a phase II study on tipifarnib for the treatment of lower risk myelodysplastic syndromes.
JNJ: 123.34 (+0.49), RTRX: 18.57 (-0.08), KURA: 3.29 (+0.40), BMY: 75.66 (+0.38)

7 Biotech Stocks that are Buys Right Now
Zacks Equity Research - Zacks Investment Research - Fri Jun 17, 10:00AM CDT
Buy these seven biotech stocks now and see how well the second half of 2016 unfolds for this industry.
MSTX: 0.49 (unch), RTRX: 18.57 (-0.08), AVEO: 0.94 (-0.01), SNSS: 0.52 (+0.01), LGND: 126.66 (+0.80), BIND: 0.55 (-0.01), ACOR: 25.97 (-0.24)

Zacks.com featured highlights: Dycom Industries, QVC Group, Retrophin, Facebook and Gener8 Maritime
Zacks Equity Research - Zacks Investment Research - Thu Jun 16, 8:30AM CDT
Zacks.com featured highlights: Dycom Industries, QVC Group, Retrophin, Facebook and Gener8 Maritime
GNRT: 5.73 (+0.33), FB: 118.21 (+0.97), RTRX: 18.57 (-0.08), QVCA: 26.26 (+0.19), DY: 96.08 (+1.10)

5 Profitable Stocks for Enhancing Your Portfolio Returns
Zacks Equity Research - Zacks Investment Research - Wed Jun 15, 7:18AM CDT
Among the profitability ratios, we have used net income ratio to determine a company's profitability position.
GNRT: 5.73 (+0.33), FB: 118.21 (+0.97), RTRX: 18.57 (-0.08), QVCA: 26.26 (+0.19), DY: 96.08 (+1.10)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Monteverde's Equity Alert: Scrutinizing Recent M&A Deals

Diving Into M&A Deals Under Monteverde's Lens Wall Street’s not just about suits and skyscrapers; it’s about the nitty-gritty of deals and whether those numbers add up in the investor's favor. So, when Monteverde & Associates PC throws its weight into scrutinizing mergers and acquisitions, you better believe it's worth a second look. See, they’re digging into four...

SiBionics and PharmaSens Unveil Diabetes Tech at EASD

Shaking Up Diabetes Care: New Tech Unveiled Imagine a world where managing diabetes isn't a juggling act with multiple devices. That's precisely the future SiBionics and PharmaSens are pitching at the European Association for the Study of Diabetes (EASD) 2026 in Milan. Now, let me tell you, these guys aren't just playing around with ideas; they're aiming to radically...

Black Culture Icon: Plastic-Covered Couch Takes Stage

A Plastic-Laden Piece of History Makes Art Who'd have thought a plastic-covered couch would turn into a cultural artifact? This iconic staple in Black households has done just that, debuting at Brooklyn's CultureCon in a fresh guise. It's more than just an upcycled furniture piece; it's a living archive that encapsulates Black culture, joy, and resilience. The Heart...

Monster Energy Dominates Skateboard Podium at SLS Paris

Monster Energy's Skateboard Triumph Hold the front page, because Monster Energy just pulled off a clean sweep in Paris. The company's team riders dominated the Men's Skateboard Street competition at the SLS Paris 2026, with the iconic Nyjah Huston snagging the top spot. It's a story filled with triumph, grit, and a dash of raw talent in a vibrant field of international...

Monteverde Probes Four Key M&A Deals for Fairness

Examining the Intricacies of Pending M&A The merger and acquisition landscape can be vicious, especially when the sharks—those pesky class action lawyers—start circling. And let me tell you, Monteverde & Associates PC is diving headfirst into the fray, launching inquiries into a handful of these deals. This isn't your first stroll down Wall Street if you’ve seen one...

ARTBOX Brings Korean Lifestyle Magic to LA Pop-Up

ARTBOX: From Seoul to La-La Land Here's what caught my eye. It's 2026, and Korean lifestyle retailer ARTBOX is making a splash in the U.S.—kicking things off with a pop-up in LA. Now, usually, I'd be skeptical about pop-ups, but you've got to admire the audacity and timing here. They've picked Melrose Avenue, a hotspot for all things trendy, to introduce their mix of...

Blokees Unveils 90+ New Wonders at Shanghai Fest

A Grand Stage for New Arrivals Picture this: In the bustling and glittering chaos that was the Wonder Festival Shanghai 2026, held from October 3 to 4, Blokees laid down a major marker. More than 500 products, an artillery of imagination and craftsmanship, were on deck across their key lines—Blokees Model Kits and BLOKEES WHEELS. With 90 brand-new creations making their...

Power Knot MEA Wins THE BIZZ 2026 for Excellence

Setting the Pace in Waste Management If there's one thing that sticks in my craw, it's how businesses handle food waste. Power Knot Middle East (PKME) seems to have cracked the code by not just leading the charge in organic waste management but also bagging THE BIZZ 2026 award. They’re not just playing industry games; PKME's pulling the strings with real leadership and...

Unpacking Monteverde's M&A Investigations Hold your horses, folks! The M&A Class Action Firm is stirring the pot with its latest inquiries into some high-profile mergers. We're looking at Lisata Therapeutics, Flag Ship Acquisition Corporation, Baldwin Insurance Group, and ACV Auctions. So what's got Juan Monteverde's legal eagles swooping in on these deals? Well, are we...

Lawsuit Highlights Inaction in School Bus Tragedy

Seeking Justice Amid Heartbreak Tragedy rarely arrives whispered on the wind—more often, it's the train wreck some saw coming long before it hits. The tragic death of Jenna Menias, a 6-year-old from Frankfort, Illinois, falls squarely in this camp. The family's legal lions, Corboy & Demetrio, have slapped two school districts—District 210 and 157-C—with a wrongful...